免疫检查点抑制剂在晚期或复发性子宫内膜癌中的作用
Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer.
作者信息
Arora Ena, Masab Muhammad, Mittar Priyanka, Jindal Vishal, Gupta Sorab, Dourado Claudia
机构信息
Obstetrics and Gynecology, Civil Hospital Chandigarh, Chandigarh, IND.
Internal Medicine, Albert Einstein Medical Center , New York, USA.
出版信息
Cureus. 2018 Apr 23;10(4):e2521. doi: 10.7759/cureus.2521.
Abstract
Currently, treatment options for patients with advanced or recurrent endometrial cancer remain limited. The current standard of care treatment for advanced endometrial carcinoma is a platinum doublet chemotherapy. Second-line treatment options overall are very limited. There is no optimal treatment option for patients who show disease progression with first-line therapy. Therefore, novel and more efficacious therapies for patients with advanced or recurrent disease are needed. Immune checkpoint inhibitors have demonstrated a very impressive safety profile and anti-tumor activity in patients with programmed death-ligand 1 (PD-L1) positive endometrial cancer who were pre-treated with chemotherapy. We have done a detailed review of the literature to emphasize the role of immune checkpoint inhibitors in the treatment of metastatic or recurrent endometrial cancer.
摘要
目前，晚期或复发性子宫内膜癌患者的治疗选择仍然有限。晚期子宫内膜癌目前的标准治疗方案是铂类双联化疗。总体而言，二线治疗选择非常有限。对于一线治疗出现疾病进展的患者，没有最佳的治疗选择。因此，需要为晚期或复发性疾病患者提供新的、更有效的治疗方法。免疫检查点抑制剂在接受过化疗预处理的程序性死亡配体1（PD-L1）阳性子宫内膜癌患者中显示出非常令人印象深刻的安全性和抗肿瘤活性。我们对文献进行了详细综述，以强调免疫检查点抑制剂在转移性或复发性子宫内膜癌治疗中的作用。
相似文献
1
Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer.
Cureus. 2018 Apr 23;10(4):e2521. doi: 10.7759/cureus.2521.
2
Immune checkpoint inhibitors for recurrent endometrial cancer.
Expert Rev Anticancer Ther. 2022 Mar;22(3):249-258. doi: 10.1080/14737140.2022.2044311. Epub 2022 Feb 24.
3
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Crit Rev Oncol Hematol. 2020 Aug;152:102973. doi: 10.1016/j.critrevonc.2020.102973. Epub 2020 May 18.
4
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
J Clin Med. 2020 Jun 3;9(6):1721. doi: 10.3390/jcm9061721.
5
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
Thorac Cancer. 2023 Mar;14(8):773-778. doi: 10.1111/1759-7714.14806. Epub 2023 Feb 1.
6
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. doi: 10.1002/14651858.CD012160.pub2.
7
A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
Oncologist. 2021 Oct;26(10):811-817. doi: 10.1002/onco.13832. Epub 2021 Jun 14.
8
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Adv Ther. 2023 Oct;40(10):4134-4150. doi: 10.1007/s12325-023-02624-9. Epub 2023 Aug 22.
9
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Gynecol Oncol. 2023 Feb;169:27-33. doi: 10.1016/j.ygyno.2022.11.031. Epub 2022 Dec 6.
10
Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Semin Respir Crit Care Med. 2020 Jun;41(3):400-408. doi: 10.1055/s-0040-1710077. Epub 2020 May 25.
引用本文的文献
1
Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7155-7164. doi: 10.1007/s00432-023-04632-2. Epub 2023 Mar 8.
2
Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer.
Front Genet. 2022 Oct 6;13:990301. doi: 10.3389/fgene.2022.990301. eCollection 2022.
3
To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy.
Front Cell Dev Biol. 2022 Jul 22;10:935650. doi: 10.3389/fcell.2022.935650. eCollection 2022.
4
Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Front Cell Dev Biol. 2021 Nov 25;9:753004. doi: 10.3389/fcell.2021.753004. eCollection 2021.
5
Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.
Sci Rep. 2021 Jun 15;11(1):12608. doi: 10.1038/s41598-021-92091-5.
6
Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors.
World J Oncol. 2020 Oct;11(5):183-187. doi: 10.14740/wjon1325. Epub 2020 Oct 15.
7
The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer.
Int J Mol Sci. 2020 Jul 29;21(15):5409. doi: 10.3390/ijms21155409.
8
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma.
Cureus. 2020 Jun 27;12(6):e8862. doi: 10.7759/cureus.8862.
9
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13.
10
The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.
Front Oncol. 2019 Oct 15;9:1073. doi: 10.3389/fonc.2019.01073. eCollection 2019.
本文引用的文献
1
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10.
2
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
3
Recent Advances in Endometrial Cancer.
F1000Res. 2017 Jan 27;6:81. doi: 10.12688/f1000research.10020.1. eCollection 2017.
4
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
J Manag Care Spec Pharm. 2017 Feb;23(2):184-194. doi: 10.18553/jmcp.2017.23.2.184.
5
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
Oncotarget. 2017 Mar 7;8(10):17313-17327. doi: 10.18632/oncotarget.14388.
6
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
7
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Cell Res. 2017 Jan;27(1):11-37. doi: 10.1038/cr.2016.155. Epub 2016 Dec 27.
8
The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
Onco Targets Ther. 2016 Sep 23;9:5867-5874. doi: 10.2147/OTT.S115262. eCollection 2016.
9
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
J Clin Invest. 2016 Jun 1;126(6):2334-40. doi: 10.1172/JCI84940. Epub 2016 May 9.
10
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
Zotero 插件